BeStock  
Stocks › Biotechnology › GMAB

Genmab GMAB

US equityMarket cap rank #628Biotechnology
$50.60 −$0.75 (-1.46%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $50.02 -1.15%
Open$51.57
Prev close$51.35
Day range$50.24 – $51.72
Volume2.90M
Market cap$31.20B
P/E (TTM)43.2
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings43.2x
CheapRich

Near the top of its 5-year range · 81st percentile, 5-year average 29.5x

#2538 of 2996 stocks by PE (1 = cheapest)

Price / book4.9x
CheapRich

Above its usual level · 60th percentile, 5-year average 4.7x

#4478 of 5338 stocks by PB (1 = cheapest)

Price / sales7.3x
CheapRich

Around its usual level · 49th percentile, 5-year average 9.3x

#4362 of 5161 stocks by PS (1 = cheapest)

P/E over five years

6x28x49x71xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$46.85
Price vs. fair value+8.0%Trading above the estimate
Star rating★★★☆☆
Economic moatWide
UncertaintyMedium
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 4.93 – 4.72 60% (pricier than usual) #4478 of 5338 (1 = cheapest)
PE 43.25 33.02 29.46 81% (pricier than usual) #2538 of 2996 (1 = cheapest)
PS 7.26 6.25 9.28 49% (cheaper than usual) #4362 of 5161 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on GMAB.

Sign in to join the discussion.

Scroll to Top